COMBINED ACAMPROSATE AND NALTREXONE, WITH COGNITIVE BEHAVIOURAL THERAPY IS SUPERIOR TO EITHER MEDICATION ALONE FOR ALCOHOL ABSTINENCE: A SINGLE CENTRES' EXPERIENCE WITH PHARMACOTHERAPY
Open Access
- 8 February 2006
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 41 (3) , 321-327
Abstract
Aims: To compare treatment outcomes amongst patients offered pharmacotherapy with either naltrexone or acamprosate used singly or in combination, in a 12-week outpatient cognitive behavioural therapy (CBT) programme for alcohol dependence. Methods: We matched 236 patients across gender, age group, prior alcohol detoxification, and dependence severity and conducted a cohort comparison study of three medication groups (CBT+acamprosate, CBT+naltrexone, CBT+combined medication) which included 59 patients per group. Outcome measures included programme attendance, programme abstinence and for those who relapsed, cumulative abstinence duration (CAD) and days to first breach (DFB). Secondary analyses compared the remaining matched 59 subjects who declined medication with the pharmacotherapy groups. Results: Across medication groups, CBT+ combined medication produced the greatest improvement across all outcome measures. Although a trend favoured the CBT+ combined group, differences did not reach statistical significance. Programme attendance: CBT + Acamprosate group (66.1%), CBT + Naltrexone group (79.7%), and in the CBT + Combined group (83.1%). Abstinence rates were 50.8, 66.1, and 67.8%, respectively. For those that did not complete the programme abstinent, the average number of days abstinent (CAD) were 45.07, 49.95, and 53.58 days, respectively. The average numbers of days to first breach (DFB) was 26.79, 26.7, and 37.32 days. When the focal group (CBT + combined) was compared with patients who declined medication (CBT-alone), significant differences were observed across all outcome indices. Withdrawal due to adverse medication effects was minimal. Conclusions: The addition of both medications (naltrexone and acamprosate) resulted in measurable benefit and was well tolerated. In this patient population naltrexone with CBT is as effective as combined medication with CBT, but the trend favours combination medication.Keywords
This publication has 18 references indexed in Scilit:
- The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol‐Dependent Individuals: Results of a Meta‐AnalysisAlcohol, Clinical and Experimental Research, 2004
- Testing Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (The COMBINE Study): A Pilot Feasibility StudyAlcohol, Clinical and Experimental Research, 2003
- Testing Combined Pharmacotherapies and Behavioral Interventions in Alcohol Dependence: Rationale and MethodsAlcohol, Clinical and Experimental Research, 2003
- Dose-Ranging Kinetics and Behavioral Pharmacology of Naltrexone and Acamprosate, Both Alone and Combined, in Alcohol-Dependent SubjectsJournal of Clinical Psychopharmacology, 2003
- Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of AlcoholismArchives of General Psychiatry, 2003
- Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved?Australian & New Zealand Journal of Psychiatry, 2002
- Outpatient Cognitive Behavioural Therapy Programme for Alcohol Dependence: Impact of Naltrexone Use on OutcomeAustralian & New Zealand Journal of Psychiatry, 2001
- Adherence with naltrexone prescription advice in hospital outpatient alcohol rehabilitation programmeJournal of Clinical Pharmacy and Therapeutics, 2001
- Contribution of Carbohydrate Deficient Transferrin to Gamma Glutamyl Transpeptidase in Evaluating Progress of Patients in Treatment For AlcoholismAlcohol, Clinical and Experimental Research, 1999
- Acamprosate in alcohol dependence: how does it work?Addiction, 1995